INCY / Incyte Is A Buy As Ruxolitinib Ramps Revenue And Pipeline Matures

Incyte's (INCY) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens Jakafi net product revenue guidance for more_horizontal

Incyte Corporation (NASDAQ:INCY ) Q3 2023 Earnings Call Transcript October 31, 2023 8:00 AM ET Company Participants Ben Strain - Head of Investor Rela more_horizontal

Incyte reported a third-quarter profit on Tuesday that beat analysts' estimates as lower costs helped offset weak sales of its blood cancer drug Jakaf more_horizontal

Incyte (INCY) came out with quarterly earnings of $1.10 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings more_horizontal

Incyte (INCY) loses 29.6% year-to-date as competition increases for Jakafi and the company suffers pipeline setbacks. more_horizontal

Incyte (INCY) announces new positive 52-week data from its mid-stage study of povorcitinib for the treatment of adult patients with extensive nonsegme more_horizontal

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and more_horizontal

Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis. more_horizontal